| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Everolimus | Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential increased risk of immunosuppressant adverse effects |
Initiate adjusted dose of immunosuppressant to account for increased concentration and follow up with therapeutic drug monitoring to refine dosing. Monitor for adverse effects of immunosuppressant. Consult with specialist as necessary. |
|||
| Darunavir Everolimus 929 | Red: Avoid combination | Do not coadminister: Potential for increased everolimus levels | Potential for increased risk of everolimus adverse effects |
Not studied |
Not studied (may increase everolimus levels) |
Use alternative agents |
|
| Elvitegravir Everolimus 244 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Increased everolimus effects (e.g. excessive immunosuppression) |
If coadministering monitor everolimus levels and adjust dose as indicated |
